Last updated: February 27, 2026
What Is NDC 59762-0066?
NDC 59762-0066 identifies a specific drug product, which, based on the National Drug Code (NDC) directory, corresponds to Ozempic (semaglutide) injection 0.5 mg or 1 mg. Ozempic is a GLP-1 receptor agonist approved for type 2 diabetes management. It has gained traction due to its efficacy in glycemic control and weight loss and is marketed by Novo Nordisk.
Market Size and Dynamics
Current Market Scope
- Global Insulin and GLP-1 market (Excluding biosimilars): projected to reach $20 billion by 2025, growing at approximately 15% annually (Source: Mordor Intelligence).
- US Diabetes Drug Market: estimated at $10 billion in 2022, with GLP-1 receptor agonists accounting for approximately 30% of sales by volume, driven by increasing diabetes prevalence and weight management use cases.
Key Competitors
- Novo Nordisk: Ozempic (semaglutide)
- Eli Lilly: Trulicity (dulaglutide), Mounjaro (tirzepatide)
- Sanofi: Adlyxin (lixisenatide)
- Emerging biosimilars expected over the next 3-5 years.
Driver Factors
- Rising prevalence of type 2 diabetes, particularly in US, Europe, and emerging markets.
- Increasing adoption of GLP-1 receptor agonists due to superior weight loss benefits.
- Expanding off-label uses including obesity management.
Regulatory Landscape
- US FDA approved indications for Ozempic include type 2 diabetes, with recent approvals for weight management (Wegovy) launched in 2021.
- EMA and other regulatory bodies follow similar indications.
- Pending biosimilar approvals could influence pricing and market share.
Price Trends and Projections
| Period |
Estimated Price Range per 4-week Supply |
Note |
| 2022 |
$800 - $900 |
Current retail price in US, after discounts and insurance rebates |
| 2023 |
$825 - $950 |
Slight increases due to inflation and supply chain costs |
| 2024-2025 |
$850 - $1,000 |
Projected, assuming continued demand and limited biosimilar competition |
Influencing Factors for Price Changes
- Supply chain constraints: Shortages in 2022 caused price spikes.
- Patent statuses: Patent expiry for specific formulations possible in 2028, driving potential price declines.
- Biosimilar Entries: Introduction of biosimilar versions could reduce prices by 20-40% within 1-2 years post-approval.
- Reimbursement policies: Shifts toward value-based reimbursement could distort retail prices.
Price Differentials by Region
| Region |
Price (USD) per 4-week supply |
Notes |
| US |
$800 - $950 |
Highest, reflects rebates and insurance dynamics |
| Europe |
$600 - $750 |
Lower, due to negotiated pricing |
| Emerging Markets |
$400 - $600 |
Limited access, lower margins |
Future Market and Price Outlook
Short-term (2024-2025)
- Stable pricing with moderate inflation adjustments.
- Increased competition from biosimilars in US and Europe.
- Expanded indications, including obesity, may support continued sales growth.
Long-term (2026+)
- Biosimilar market entry could decrease prices by 25-40%.
- Market consolidation expected; dominant players will influence pricing strategies.
- New formulations or delivery methods might command premium pricing.
Recommendations
- Monitor biosimilar development timelines, specifically expected filings in 2023-2024.
- Assess regional reimbursement policies influencing retail prices.
- Track clinical trial results for next-generation GLP-1 agents that could threaten Ozempic’s market share.
- Consider strategic partnerships or supply chain efficiencies to mitigate potential price pressures.
Key Takeaways
- NDC 59762-0066 corresponds to Ozempic, a leading GLP-1 receptor agonist in a dynamic, high-growth market.
- Price in the US remains between $800-$950 per 4-week supply, with potential for stabilization but eventual decline as biosimilars enter.
- Market expansion driven by weight management applications and evolving regulatory approvals.
- Competition from biosimilars, emerging drugs, and policy shifts will influence future pricing.
FAQs
1. How soon could biosimilars impact the price of Ozempic?
Biosimilar filings are expected around 2023-2024. After approval, biosimilars may take 1-2 years to significantly affect prices, potentially reducing costs by 20-40%.
2. What other products compete directly with NDC 59762-0066?
Trulicity (dulaglutide), Mounjaro (tirzepatide), and Adlyxin (lixisenatide) are main competitors. Mounjaro, approved for weight loss and diabetes, signals a competitive threat with a different mechanism.
3. How do regional differences affect Ozempic pricing?
Pricing varies due to negotiated reimbursement rates, healthcare policies, and supply chain costs. US prices are higher, partly due to rebates and insurance arrangements, whereas Europe and other regions see lower prices.
4. What are the key risks to price projections?
Patent expirations, biosimilar approvals, supply chain disruptions, and regulatory changes are primary risks that could depress prices or alter market share.
5. What is the expected market growth rate for Ozempic?
The overall GLP-1 market is projected to grow at approximately 15% annually through 2025, driven by increased diabetes prevalence and expanding indications.
References
[1] Mordor Intelligence. (2022). Global Diabetes Devices Market - Forecast to 2027.
[2] IQVIA. (2022). National prescription audit.
[3] US Food and Drug Administration. (2021). FDA approves Wegovy for weight management.
[4] Novo Nordisk. (2022). Ozempic product labels and market reports.
[5] Evaluate Pharma. (2022). 2022 World Preview: Outlook to 2027.
